Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...